Spherix Global Insights

September 16, 2021

Biogen’s Alzheimer’s Drug Aduhelm Slowly Gaining Steam Among Prescribing Neurologists, Study Finds

From: FiercePharma


Chiasma secures FDA approval for acromegaly pill Mycapssa years after near-catastrophic rejection | LifeSci Communications


A week ago, Biogen CEO Michel Vounatsos sent the company’s shares into a nosedive after disclosing its launch of Alzheimer’s disease med Aduhelm was slower than expected. But according to one new analysis, there may be signs things are looking up.

Data collected from a survey of 74 neurologists collected at the start of the month found that at least two thirds of respondents anticipate having at least some patients on Aduhelm by March 2022, according to Spherix Global Insights’ newly launched drug report released on Thursday. That could result in “an estimated brand share substantially higher than that projected back in August,” the report found…(read more)